Pharma Major, Zydus Cadila has received the final approval from the USFDA to market Risedronate Sodium Delayed-Release Tablets (US RLD ATELVIA delayed-release tablets), 35 mg.
It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, company said in a filing with BSE.
Risedronate is a medicine of bisphosphonate group that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. This medicine is used to treat osteoporosis in women, caused by menopause.
The group now has 218 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.